Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Neurodegenerative Diseases: full-pipeline trial registry
8 of 13 indexed Neurodegenerative Diseases trials are currently recruiting.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 8 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Neurodegenerative Diseases: 13 US clinical trials tracked, 8 recruiting.
Neurodegenerative Diseases is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Elizabeth K Rhodus, running 1 of these trials.
Enrollment posture brief
Registry condition neurodegenerative-diseases
OPEN 8 | RECR 62% | LATE 2 | EARLY 2 | RANK #1315 | SPON 1
Volume-matched condition peers
Nearest open-share peer: High Risk Myelodysplastic Syndrome (62% recruiting · 13 trials)
Neurodegenerative Diseases lists 8 open slots (62% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Neurodegenerative Diseases on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Neurodegenerative Diseases is recruiting above its size-band peers.
8 of 13 indexed trials (61.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Neurodegenerative Diseases trials is spread across many organizations.
Elizabeth K Rhodus accounts for 1 of 13 trials (7.7%). 13 distinct sponsors appear on at least one study for this condition label.
-
Typical Neurodegenerative Diseases enrolment sits around 100 participants.
Median target enrolment is 100 among the 13 trials that report a genuine target (sentinel values excluded). 6 of those (46.2%) plan for fewer than 100 participants.
-
Neurodegenerative Diseases research is mostly interventional.
10 interventional and 3 observational studies make up this index (76.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Observational Pharmaco-Epidemiology Research & Analysis
Epividian
NCT03813862
Neurologic Stem Cell Treatment Study
MD Stem Cells
NCT02795052
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Boston Children's Hospital
NCT05354622
Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease
University of Arizona
NCT04838301
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Vanderbilt University Medical Center
NCT05357612
Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia
University of Texas at Austin
NCT05741853
Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside
Mclean Hospital
NCT05245903
Home Exercise for Individuals with Neurodegenerative Disease
Hugo W. Moser Research Institute at Kennedy Krieger
NCT05443906
Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)
Sage Bionetworks
NCT02696603
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company
NCT05738486
AMX0035 and Progressive Supranuclear Palsy
Amylyx Pharmaceuticals
NCT06122662
Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers
Elizabeth K Rhodus
NCT05202223
Assessing a Novel Virtual Environment That Assists With Activities of Daily Living
mandy
NCT05418296
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Neurodegenerative Diseases records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Neurodegenerative Diseases trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Neurodegenerative Diseases page
13 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Neurodegenerative Diseases trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Elizabeth K Rhodus sponsors the most Neurodegenerative Diseases trials on record, review their full trial history before evaluating a specific study. See Elizabeth K Rhodus's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Neurodegenerative Diseases condition card totals 13 registered trials; most-linked intervention Placebo; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.